Institutional News

Last Days to Sign Up to SOLACI-SOCIME 2022 with 15% OFF

solaci
solaci
400
0

SOLACI-SOCIME 2022

LAST DAYS TO SIGN UP WITH 15% OFF

We are a little less than one month away from the most relevant meeting of interventional cardiology in Latin America.

This year we celebrate the long-awaited return to our face to face meetings. This is why we have prepared an innovative scientific program with challenging live and edited cases, prestigious international guests, outstanding symposia with the most relevant topics in the field, interesting academic debates and much more.

Do not miss this unique opportunity to make part of this event with 15% discount.

Register Now with 15% Discount

Discover the Preliminary Program

MORE INFORMATION ON THE CONGRESS

Call For Science – Last Days
Send your work before July 15 and introduce yourself to your colleagues around the world as an expert.
Send Your Work Now 

 

Live Cases
We will be broadcasting challenging live cases from 4 specialized centers in México and from Argentina.
Read Moreae

 

Sponsored Scientific Activities
Find out about innovative sessions in interventional cardiology sponsored by the industry.
Read More

 

Highlights | Why attend?
Find out why you cannot miss this event in the following link.
Read More 

 

Lodging Options
Book your stay in Mexico during SOLACI-SOCIME 2022 at the best hotels in the city at a special rate.
Read More

 

Register Now with 15% off

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
Same Day Discharge in NSTE-ACS: Is It Possible?
Next article
Watch again Disruptive and Conventional Treatments Below The Knee and in the Superficial Femoral Artery – SOLACI Webinar
solaci
solaci

More articles by this author

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

solaci - 0
The Latin American Society of Interventional Cardiology invites the entire medical community to participate in a virtual workshop on complications organized by SOLACI’s Complex...

Fellow’s Corner 2026 – Submit Your Clinical Case

solaci - 0
Share your experience. Learn from experts. Grow as an interventional cardiologist. The Latin American Society of Interventional Cardiology (SOLACI) is relaunching this year the Fellow’s...

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

solaci - 0
The webinar “Cardiovascular Risk Factors in Women,” held on January 27, 2026, via the Zoom platform, is now available for viewing on SOLACI’s YouTube...

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

solaci - 0
The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

CHIP LATAM News

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

The Latin American Society of Interventional Cardiology invites the entire medical community to participate in a virtual workshop on complications...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Dr. Juan Manuel Pérez - 0
Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Dr. Andrés Rodríguez - 0
Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...